5-bromo-8-methoxycoumarin-3-carboxylic acid

5-bromo-8-methoxycoumarin-3-carboxylic acid is a synthetic small molecule derivative of the 8-methoxycoumarin scaffold, specifically designed as a potential anti-hepatocellular carcinoma (HCC) agent. It was synthesized through the halogenation of 8-methoxycoumarin-3-carboxylic acid using bromine in glacial acetic acid. Within its chemical class, it is intended to act by inhibiting β-tubulin polymerization and activating executioner caspases (caspase-3/7) to trigger programmed cell death (apoptosis) in malignant cells. However, in antiproliferative assays against the HepG2 liver cancer cell line, this specific carboxylic acid derivative demonstrated significantly lower potency (IC50 = 41 µM) compared to its carboxamide counterparts, such as compound 5, suggesting that the carboxylic acid moiety at position-3 may negatively impact binding affinity or cellular uptake in this specific structural context.